Authors:
Aparicio, T
Ducreux, M
Baudin, E
Sabourin, JC
De Baere, T
Mitry, E
Schlumberger, M
Rougier, P
Citation: T. Aparicio et al., Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours, EUR J CANC, 37(8), 2001, pp. 1014-1019
Authors:
Karoui, M
Hofmann-Radvanyi, H
Zimmermann, U
Couvelard, A
Degott, C
Faridoni-Laurens, L
Ahomadegbe, JC
Gazzeri, S
Brambilla, E
Clerici, T
Charbonnier, P
Tresallet, C
Mitry, E
Penna, C
Rougier, P
Boileau, C
Thiery, JP
Nordlinger, B
Franc, B
Radvanyi, F
Citation: M. Karoui et al., No evidence of somatic FGFR3 mutation in various types of carcinoma, ONCOGENE, 20(36), 2001, pp. 5059-5061
Authors:
Mitry, E
Benhamiche, AM
Jouve, JJ
Clinard, F
Finn-Faivre, C
Faivre, J
Citation: E. Mitry et al., Colorectal adenocarcinoma in patients under 45 years of age: Comparison with older patients in a well-defined French population, DIS COL REC, 44(3), 2001, pp. 380-387
Authors:
Finn-Faivre, C
Maurel, J
Benhamiche, AM
Herbert, C
Mitry, E
Launoy, G
Faivre, J
Citation: C. Finn-faivre et al., Evidence of improving survival of patients with rectal cancer in France: apopulation based study, GUT, 44(3), 1999, pp. 377-381
Authors:
Faivre, C
Rougier, P
Ducreux, M
Mitry, E
Lusinchi, A
Lasser, P
Elias, D
Eschwege, F
Citation: C. Faivre et al., 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer, B CANCER, 86(10), 1999, pp. 861-865
Authors:
Mitry, E
Baudin, E
Ducreux, M
Sabourin, JC
Rufie, P
Aparicio, T
Lasser, P
Elias, D
Duvillard, P
Schlumberger, M
Rougier, P
Citation: E. Mitry et al., Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin, BR J CANC, 81(8), 1999, pp. 1351-1355
Authors:
Rougier, P
Mitry, E
Clavero-Fabri, MC
Penna, C
Nordlinger, B
Citation: P. Rougier et al., Established data and practical recommendations for neoadjuvant and adjuvant chemotherapy for rectal cancer., ANN CHIR, 53(10), 1999, pp. 1011-1018
Citation: E. Mitry et al., Irinotecan as second-line chemotherapy after failure to 5FU for metastaticcolorectal cancer: phase III trials, B CANCER, 1998, pp. 38-42